Bridgefront Capital, LLC Day One Biopharmaceuticals, Inc. Transaction History
Bridgefront Capital, LLC
- $278 Million
- Q4 2024
A detailed history of Bridgefront Capital, LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Bridgefront Capital, LLC holds 18,874 shares of DAWN stock, worth $231,395. This represents 0.09% of its overall portfolio holdings.
Number of Shares
18,874Holding current value
$231,395% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
175Shares Held
77.8MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$78.8 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$71.7 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$70.6 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$59.8 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$55.6 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $901M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...